JPM 2024 BioNTech-1704871319.pdf

1、42nd J.P.Morgan Healthcare ConferenceProf.Ugur Sahin,M.D.CEO&Co-founder9 January 20249:00 9:40 AM PSTThis Slide Presentation Includes Forward-Looking Statements2This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,as amended

2、,including,but not limited to,statements concerning:planned next steps in BioNTechs pipeline programs,including,but not limited to,statements regarding timing or plans for initiation of clinical trials,enrollment or submission for,and receipt of product approvals with respect to BioNTechs product ca

3、ndidates;BioNTechs estimates of certain financial information,including financial guidance for full year 2024 revenue,which includes expected revenues related to sales of BioNTechs COVID-19 vaccine(referred to as COMIRNATY where approved for use under full or conditional marketing authorization)in t

4、erritories controlled by BioNTechs collaboration partners,particularly for those figures that are derived from preliminary estimates provided by BioNTechs partners;the rate and degree of market acceptance of BioNTechs COVID-19 vaccine and,if approved,BioNTechs investigational medicines;expectations

5、regarding anticipated changes in COVID-19 vaccine demand,including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages;the registrational potential of any trials BioNTech may initiate;the initiation,timing,progress,resu

6、lts,and cost of BioNTechs research and development programs,including statements regarding the timing of initiation and completion of studies or trials and related preparatory work,the availability of results,and characterization and timing of clinical data;BioNTechs targeted timing for a potential